METHYLENE BLUE (methylene blue) by Chengdu New Radiomedicine is non-enzymatic redox conversion of methb to hemoglobin. First approved in 2025.
Drug data last refreshed 19h ago
non-enzymatic redox conversion of metHb to hemoglobin. In situ, methylene blue is first converted to leucomethylene blue (LMB) via NADPH reductase. It is the LMB molecule which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
Methylene Blue Against Falciparum Malaria in Burkina Faso
Phase 2 Efficacy Study of Primaquine and Methylene Blue
Methylene Blue Against Vivax Malaria in Ethiopia
Worked on METHYLENE BLUE at Chengdu New Radiomedicine? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.